Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.
With its new focus on India, ResearchDx plans to offer local drugmakers the chance to develop tests to help target their in-development therapies, betting on the country's burgeoning biotech industry. Furthermore, ResearchDx offers offers lab validation services, assisting clients in obtaining the CLIA, CAP or ISO certifications they need to do business in the West, co-founder Philip Cotter said.
"We can provide a strategic partnership to Indian companies looking to develop companion diagnostics or in vitro diagnostic products for the local, U.S. or European markets," Cotter said in a statement. "We provide a full range of companion diagnostics and in vitro diagnostics services."
Diagnostics development has long been dominated by drugmakers with in-house departments, like Roche ($RHHBY) and Abbott Laboratories ($ABT), or test-focused companies like Qiagen ($QGEN) and bioMérieux. Now, ResearchDx is counting on the increasing popularity of personalized medicine to create an avenue for contractors to step in and develop diagnostics with speed and efficiency.
Over the summer, the California company cut the ribbon on a 30,000-square-foot facility in Irvine, increasing its footprint to provide services from initial assay conceptualization, discovery, optimization and validation to regulatory approvals.
- read the announcement